NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

BIIB

Biogen Inc

Jun 30 • 04:00PM ET

125.59

Dollar change -0.49
Percentage change -0.39	%

Healthcare • Drug Manufacturers - General • USA • NASD

Peers: VRTX GILD REGN AMGN MRK PFE BMY LLY JNJ NBIX

| Held by: VTI VOO VO QQQ SPY IVV VTV COWZ RSP XLV

Scroll to Statements

Index	NDX, S&P 500	P/E	12.40	EPS (ttm)	10.13	Insider Own	0.19%	Shs Outstand	146.50M	Perf Week	0.67%
Market Cap	18.40B	Forward P/E	8.14	EPS next Y	15.43	Insider Trans	-3.91%	Shs Float	146.25M	Perf Month	-5.39%
Enterprise Value	22.43B	PEG	-	EPS next Q	4.07	Inst Own	89.93%	Short Float	2.32%	Perf Quarter	-9.24%
Income	1.48B	P/S	1.96	EPS this Y	-9.99%	Inst Trans	-1.32%	Short Ratio	2.07	Perf Half Y	-15.72%
Sales	9.40B	P/B	1.08	EPS next Y	4.05%	ROA	5.42%	Short Interest	3.39M	Perf YTD	-17.87%
Book/sh	115.90	P/C	7.08	EPS next 5Y	-0.76%	ROE	9.19%	52W High	238.00 -47.23%	Perf Year	-44.05%
Cash/sh	17.73	P/FCF	7.55	EPS past 3/5Y	2.46% -18.66%	ROIC	6.77%	52W Low	110.04 14.14%	Perf 3Y	-39.33%
Dividend Est.	-	EV/EBITDA	7.80	Sales past 3/5Y	-3.78% -6.13%	Gross Margin	66.54%	Volatility	2.12% 2.35%	Perf 5Y	-53.66%
Dividend TTM	-	EV/Sales	2.39	EPS Y/Y TTM	26.10%	Oper. Margin	22.62%	ATR (14)	3.18	Perf 10Y	-66.04%
Dividend Ex-Date	-	Quick Ratio	1.01	Sales Y/Y TTM	1.25%	Profit Margin	15.73%	RSI (14)	44.05	Recom	2.06
Dividend Gr. 3/5Y	- -	Current Ratio	1.44	EPS Q/Q	-39.16%	SMA20	-3.10%	Beta	0.14	Target Price	170.22
Payout	0.00%	Debt/Eq	0.39	Sales Q/Q	6.17%	SMA50	0.08%	Rel Volume	0.70	Prev Close	126.08
Employees	7605	LT Debt/Eq	0.29	Earnings	May 01 BMO	SMA200	-15.85%	Avg Volume	1.64M	Price	125.59
IPO	Sep 17, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.16% 8.81%	Trades		Volume	1,184,454	Change	-0.39%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-28-25	Downgrade	HSBC Securities	Buy → Hold	$118
Apr-04-25	Downgrade	Argus	Buy → Hold
Feb-11-25	Initiated	Bernstein	Mkt Perform	$160
Jan-02-25	Downgrade	Piper Sandler	Overweight → Neutral	$315 → $138
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$230 → $164
Dec-16-24	Downgrade	Stifel	Buy → Hold	$175
Dec-10-24	Resumed	BofA Securities	Neutral	$178
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$250 → $180
Nov-18-24	Downgrade	Needham	Buy → Hold
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-14-24	Initiated	Citigroup	Neutral	$190
Oct-31-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$285 → $204
Oct-10-24	Resumed	Raymond James	Mkt Perform
Feb-14-24	Reiterated	Needham	Buy	$305 → $300
Feb-14-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$315 → $240
Jan-24-24	Downgrade	UBS	Buy → Neutral	$311 → $276
Dec-20-23	Resumed	Cantor Fitzgerald	Overweight	$311
Dec-07-23	Upgrade	Raymond James	Mkt Perform → Outperform	$283
Sep-06-23	Initiated	HSBC Securities	Buy	$360
Jul-27-23	Initiated	Scotiabank	Sector Outperform	$327

Show Previous Ratings

Today 12:03AM	3 Reasons BIIB is Risky and 1 Stock to Buy Instead (StockStory)
Jun-30-25 08:42AM	AbbVie to buy Capstan for up to $2.1 billion in immunology push (Reuters)
08:18AM	RBC says Lilly could blaze trail and Biogen could pull ahead in Alzheimers market (Investing.com)
07:30AM	Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy (GlobeNewswire)
Jun-28-25 10:05AM	Biogen highlights promising results for higher-dose nusinersen in SMA trials (TipRanks)
04:16AM	Loading…
04:16AM	Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results (Insider Monkey)
Jun-27-25 10:00AM	New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA (GlobeNewswire)
Jun-26-25 03:46AM	5 Revealing Analyst Questions From Biogen's Q1 Earnings Call (StockStory)
Jun-25-25 04:46PM	Biogen's Friedreich's Ataxia Campaigns Earn 4 Cannes Lions Pharma Nominations (Insider Monkey)
04:19PM	Can Biogen Save Even More Kids With This New Drug? (Investor's Business Daily)
11:41AM	Biogens Spinraza successor advances to Phase III (Clinical Trials Arena)
10:47AM	Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics (GlobeNewswire)
07:33AM	Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? (Investor's Business Daily)
07:31AM	Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results (Business Wire)
07:30AM	Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results (GlobeNewswire)
03:36AM	Loading…
Jun-24-25 03:36AM	Biogen scores Cannes Festival win with dark humored campaign (Pharma Voice)
Jun-23-25 01:36AM	Biogen Launches Phase 3 Pediatric Trial Of Omaveloxolone For Friedreich Ataxia. (Insider Monkey)
Jun-19-25 07:38AM	Biogen starts dosing in Phase III trial of Friedreich ataxia therapy (Clinical Trials Arena)
Jun-18-25 11:08AM	21GRAMS Wins Its First Gold Lion for Branded Pharma Campaign at Cannes Lions International Festival of Creativity (Business Wire)
09:45AM	H.C. Wainwright sees potential competition for Sage from Biogen (TipRanks)
07:30AM	Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia (GlobeNewswire)
Jun-17-25 02:36PM	SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal (Zacks)
11:20AM	Biogen Targets Rare Diseases, Eyes $800M Cost Cuts With 'Fit for Growth' Plan (Insider Monkey)
08:00AM	Maxion Therapeutics Appoints Dr. Stefan Härtle as Chief Development Officer (GlobeNewswire)
Jun-16-25 04:21PM	Supernus Pharmaceuticals Snaps Up Beleaguered Sage Therapeutics (Investor's Business Daily)
11:43AM	Supernus makes depression drug play with $795m Sage buyout (Pharmaceutical Technology)
09:14AM	Beleaguered Sage Snapped Up In Deal Worth Up To $561 Million (Investor's Business Daily)
08:17AM	Sage, following Setbacks, to sell to Supernus for $561M (BioPharma Dive)
Jun-15-25 05:38AM	Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025 (Insider Monkey)
Jun-12-25 01:00AM	Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity (GlobeNewswire)
11:30AM	Loading…
Jun-05-25 11:30AM	Why Is Krystal Biotech (KRYS) Down 3.5% Since Last Earnings Report? (Zacks)
Jun-03-25 07:00AM	Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors (GlobeNewswire)
May-29-25 11:34PM	Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks (StockStory)
May-28-25 05:24AM	Biogen and City Therapeutics to develop RNAi therapy (Pharmaceutical Technology)
May-27-25 07:58PM	Biogen Inc. (BIIB) Taps RNAi Therapy in City Therapeutics Deal (Insider Monkey)
07:53AM	Biogen strikes RNAi deal with City; Aurion withdraws IPO (BioPharma Dive)
07:30AM	Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies (GlobeNewswire)
May-22-25 10:14AM	Sanofi to Join Alzheimer's Space With Vigil Neuroscience Buyout (Zacks)
May-20-25 08:58AM	Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study (Zacks)
May-13-25 04:58PM	Why Biogen Inc. (BIIB) Is Among the Best Pharma Stocks to Invest in Amid the Domestic Manufacturing Boom (Insider Monkey)
May-12-25 08:00AM	How To Invest: Using Shorter-Term Moving Averages To Trade Stocks (Investor's Business Daily) +5.27%
May-08-25 11:51PM	Q1 2025 Royalty Pharma PLC Earnings Call (Thomson Reuters StreetEvents)
May-07-25 01:10PM	Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus (Zacks)
May-06-25 12:32AM	2 Mid-Cap Stocks to Keep an Eye On and 1 to Ignore (StockStory)
May-05-25 02:19PM	Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement (Seeking Alpha)
May-04-25 12:00PM	4 Stocks to Buy for a Potential Summer Panic (InvestorPlace)
May-02-25 03:05AM	Biogen Inc (BIIB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst MS Franchise ... (GuruFocus.com)
12:43AM	Q1 2025 Biogen Inc Earnings Call (Thomson Reuters StreetEvents)
May-01-25 02:07PM	Biogens Q1 revenue soars past estimates as rare disease pivot pays off (Pharmaceutical Technology)
12:44PM	BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut (Zacks)
11:38AM	Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript (Seeking Alpha)
10:42AM	Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View (Zacks)
09:30AM	Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:28AM	Is Biogen At The 'Start Of A Turnaround' On Its Quarterly Beat? (Investor's Business Daily)
08:05AM	Biogen Inc. (BIIB) Q1 Earnings Lag Estimates (Zacks)
06:48AM	Biogen's results beat estimates on strength in rare disease drugs (Reuters)
06:45AM	Biogen Easily Tops Earnings Forecasts As Leqembi, Skyclarys Sales Soar (Investor's Business Daily)
Apr-30-25 12:17PM	Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y (Zacks)
09:15AM	Unveiling Biogen (BIIB) Q1 Outlook: Wall Street Estimates for Key Metrics (Zacks)
08:05AM	Q1 2025 SAGE Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-29-25 10:01AM	Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? (Zacks)
06:32AM	The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron (Zacks)
Apr-28-25 12:08PM	Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts? (Zacks)
Apr-25-25 09:15AM	Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent? (Seeking Alpha)
Apr-24-25 10:01AM	Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline (Zacks)
06:53AM	Can Biogen Keep the Beat Streak Alive This Earnings Season? (Zacks)
04:54AM	Biogens Friedreichs ataxia treatment authorised in UK (Pharmaceutical Technology)
Apr-17-25 11:07AM	Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade (Seeking Alpha)
Apr-16-25 01:07PM	Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News (Zacks)
11:49AM	Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi (Zacks)
09:45AM	EC authorises Eisai and Biogens lecanemab for Alzheimers (Pharmaceutical Technology)
09:13AM	European regulators OK Alzheimer's treatment Leqembi after initial doubts (Associated Press Finance)
Apr-15-25 07:00PM	Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union (GlobeNewswire)
Apr-11-25 06:56AM	Alzheons Alzheimers pill fails in Phase III trial (Clinical Trials Arena)
Apr-10-25 12:01PM	Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks. (Investor's Business Daily) -5.90%
09:53AM	Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock? (Zacks)
Apr-09-25 05:11PM	Sage Therapeutics: A Speculative Play That Needs To Wait For A Turnaround Story (Seeking Alpha) +5.65%
05:34AM	Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag (Seeking Alpha)
Apr-04-25 07:49PM	Analyst Report: Biogen Inc. (Morningstar Research) -5.91%
11:49AM	Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell? (Investor's Business Daily)
Apr-03-25 10:48AM	BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag (Zacks)
06:33AM	FDA grants fast track status to Biogen's BIIB080 for Alzheimer's (Pharmaceutical Business Review)
Apr-02-25 10:01AM	Organon acquires Actemra biosimilars US rights from Biogen (Pharmaceutical Technology)
07:30AM	Biogens Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimers Disease (GlobeNewswire)
Apr-01-25 07:30AM	Organon Acquires TOFIDENCE (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA (tocilizumab) Injection, for Intravenous Infusion in the U.S. (Business Wire)
Mar-31-25 10:00AM	Is the Future Bleak for SAVA Stock Following Another Setback? (Zacks)
Mar-28-25 08:13AM	Lilly hits same Alzheimers roadblock in Europe as Eisai, Biogen (BioPharma Dive)
12:55AM	ClearBridge Growth ESG Portfolios Q4 2024 Commentary (Seeking Alpha)
Mar-27-25 04:14PM	Biogen: Balancing Risks And Opportunities (SeekingAlpha)
09:15AM	Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025 (Motley Fool)
08:31AM	IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to Sobi (Zacks)
08:15AM	BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-26-25 07:43AM	SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study (Zacks)
Mar-24-25 07:58AM	Biogen plots new global headquarters in Kendall Square (BioPharma Dive)
07:30AM	Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square (GlobeNewswire)
Mar-20-25 11:30AM	Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound? (Zacks)
05:12AM	Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks (StockStory)
Mar-19-25 10:30AM	Biogen Inc. (BIIB): Among the Most Undervalued Biotech Stocks to Invest In (Insider Monkey)
Mar-18-25 07:35AM	Health Canada approves Biogens Skyclarys for Friedreichs ataxia (Pharmaceutical Technology)
Mar-14-25 11:30AM	Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report? (Zacks)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Singhal Priya	Head of Development	May 19 '25	Sale	126.25	3,806	480,508	5,427	May 20 04:05 PM
Singhal Priya	Officer	May 19 '25	Proposed Sale	126.25	3,806	480,508		May 19 11:24 AM
Keeney Adam	Head of Corporate Development	May 01 '25	Option Exercise	0.00	938	0	2,838	May 05 04:19 PM
DORSA CAROLINE	Director	May 02 '25	Buy	122.72	1,235	151,559	27,842	May 05 04:17 PM
SHERWIN STEPHEN A	Director	Mar 07 '25	Sale	150.02	8,760	1,314,142	11,318	Mar 10 04:09 PM
STEPHEN A SHERWIN	Director	Mar 07 '25	Proposed Sale	147.37	8,760	1,290,961		Mar 07 04:18 PM
Singhal Priya	Head of Development	Feb 10 '25	Option Exercise	0.00	1,212	0	9,423	Feb 12 05:48 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 10 '25	Option Exercise	0.00	2,272	0	14,725	Feb 12 05:47 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 10 '25	Option Exercise	0.00	3,257	0	25,712	Feb 12 05:46 PM
Kramer Robin	Chief Accounting Officer	Feb 10 '25	Option Exercise	0.00	834	0	8,257	Feb 12 05:44 PM
Gregory Ginger	EVP, Human Resources	Feb 10 '25	Option Exercise	0.00	2,159	0	18,232	Feb 12 05:43 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 10 '25	Option Exercise	0.00	2,575	0	37,072	Feb 12 05:42 PM
Izzar Rachid	Head of Global Product Strat.	Feb 10 '25	Option Exercise	0.00	1,515	0	8,998	Feb 12 05:40 PM
Izzar Rachid	Head of Global Product Strat.	Feb 07 '25	Option Exercise	0.00	3,844	0	7,860	Feb 11 09:52 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 07 '25	Option Exercise	0.00	4,551	0	23,171	Feb 10 06:59 PM
Viehbacher Christopher	President and CEO	Feb 07 '25	Option Exercise	0.00	9,008	0	16,008	Feb 10 06:55 PM
Grogan Jane	Head of Research	Feb 07 '25	Option Exercise	0.00	1,385	0	1,876	Feb 10 06:52 PM
Keeney Adam	Head of Corporate Development	Feb 07 '25	Option Exercise	0.00	1,801	0	2,463	Feb 10 06:51 PM
Kramer Robin	Chief Accounting Officer	Feb 07 '25	Option Exercise	0.00	1,491	0	7,667	Feb 10 06:48 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 07 '25	Option Exercise	0.00	4,042	0	13,056	Feb 10 06:47 PM
Singhal Priya	Head of Development	Feb 07 '25	Option Exercise	0.00	2,216	0	8,892	Feb 10 06:45 PM
Gregory Ginger	EVP, Human Resources	Feb 07 '25	Option Exercise	0.00	3,436	0	16,633	Feb 10 06:44 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 07 '25	Option Exercise	0.00	4,130	0	35,088	Feb 10 06:42 PM
Singhal Priya	Head of Development	Jan 31 '25	Option Exercise	0.00	1,828	0	7,254	Feb 03 06:02 PM
Singhal Priya	Head of Development	Dec 06 '24	Option Exercise	0.00	426	0	5,742	Dec 09 04:57 PM
Singhal Priya	Head of Development	Dec 09 '24	Sale	157.21	110	17,293	5,426	Dec 09 04:57 PM
Kramer Robin	Chief Accounting Officer	Dec 06 '24	Option Exercise	0.00	351	0	6,578	Dec 09 04:56 PM
Singhal Priya	Officer	Dec 09 '24	Proposed Sale	157.21	110	17,293		Dec 09 10:33 AM
Grogan Jane	Head of Research	Nov 01 '24	Option Exercise	0.00	695	0	695	Nov 04 04:39 PM
Singhal Priya	Head of Development	Aug 30 '24	Option Exercise	0.00	1,668	0	6,554	Sep 05 06:00 AM
Singhal Priya	Head of Development	Sep 03 '24	Sale	204.22	431	88,019	5,316	Sep 05 06:00 AM
Singhal Priya	Officer	Sep 03 '24	Proposed Sale	204.22	431	88,019		Sep 03 01:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BIIB

Biogen Inc

Upgrade your FINVIZ experience